An Open-label Study to Assess the Effect of AZD0780 on the Pharmacokinetics of AZD4954 and Vice Versa in Healthy Adults.
AstraZeneca
Summary
The purpose this study is to measure the impact of laroprovstat (AZD0780) on the pharmacokinetics (PK) of AZD4954 and the impact of AZD4954 on the PK of laroprovstat in healthy male and female participants.
Description
This is an open-label, fixed-sequence, 2 period and 2 cohort study in healthy participants. Each participant in each cohort will receive treatments in a fixed order during the 2 treatment periods as follows: * Cohort 1: Treatment A followed by Treatment C. * Cohort 2: Treatment B followed by Treatment C. The following treatments will be given during the study: * Treatment A: single dose of AZD4954 alone. * Treatment B: single dose of laroprovstat alone. * Treatment C: single doses of laroprovstat + AZD4954. The study will comprise of a Screening Period, two Treatment Periods and follow-up…
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * All females must have a negative pregnancy test at the Screening Visit. * Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception. * Females of non-childbearing potential must be confirmed as postmenopausal or have documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion. * Sexually active fertile male participants with partners of childbearing potential must adhere to…
Interventions
- DrugAZD4954
AZD4954 will be administered orally.
- DrugLaroprovstat
Laroprovstat will be administered orally.
Location
- Research SiteGlendale, California